

Bioavailability enhancement of poorly water soluble drugs (BCS Class II and IV Drugs) using hot-melt extrusion (HME): The cost effective approach

Devendra Ridhurkar

Pharmaceutical Development Division, Neurax Pharmaceuticals, Barcelona.Spain

Abstract:

For orally administered drugs, solubility and permeability is one of the rate-limiting factors to achieve their desired concentration in systemic circulation for pharmacological response. Poor solubility of BCS class II and IV drugs is attributable for delay or failure and due to this reason formulation scientist faces a major challenge to develop a formulation with good bioavailability. Enhancement of solubility and bioavailability of poorly soluble drugs can be achieved by amorphous solid dispersions which are prepared by converting the poorly water-soluble crystalline form into a more soluble amorphous form within the polymeric blends. Hot Melt Extrusion (HME) has been widely used to prepare amorphous solid dispersions for the improvement of solubility and dissolution rates of poorly soluble materials. During the melt extrusion process, the dissolution of APIs into the polymer matrix is accelerated under the influence of shear and heat. HME has gained popularity in the pharmaceutical industry as a means of improving the bioavailability of drugs due to its wide applications, simple process and low costs. HME is an efficient technology for producing solid molecular dispersions with considerable advantages including the absence of solvents, few processing steps, and continuous operation over solvent-based processes such as spray drying and co-precipitation. Also, HME is one of the recommended processes by FDA to encourage move from batch-to-continuous manufacturing. Moreover, it can be used to earn intellectual property and to make the noninfringing strategies for products development with ANDA para IV fillings. Marketed formulations Kaletra® and Onmel® which are prepared by HME technology, are the classical examples.

Biography:

Dr. Ridhurkar works as an Expert Scientist at Neurax

[3rd International Conference on Pharmaceutical Research & Innovations in Pharma Industry](#)

[&](#)

[6th International Conference on Antibiotics & Antibiotic Resistance; August 28-29, 2020](#)

Citation: Devendra Ridhurkar; Bioavailability enhancement of poorly water soluble drugs (BCS Class II and IV Drugs) using hot-melt extrusion (HME): The cost effective approach; Pharma Research 2020 and Antibiotics Resistance 2020; August 28-29, 2020

Pharm., Barcelona. He is responsible for development of a value-added complex formulations. He has over 13 years of experience and was associated with various reputed pharmaceutical companies like Egis, Hungary, Dr. Reddys, India. He is expert in using platform technologies like hot melt extrusion, nanotechnology, and cyclodextrin complexation. He obtained his M. Pharm, Ph.D. degree in Pharmaceutics from IIT, Varanasi, India. He is a member of editorial board for various pharmaceutical journals and has earned to his credit over 8 peer-reviewed papers in reputed international and national journals and 5 patents to his credit. He has been associated with various pharmaceutical bodies in India and American Association of Pharmaceutical Scientists. He is a member of programme advisory committee for Pharma Connect Congress, Hungary and has attended and delivered seminars and presentations at various national and international conferences.

Publication of speakers:

1. Ridhurkar D, Vajdai A, Zsigmond Z (2016) Hot-melt extrusion (HME) and its application for pharmacokinetic improvement of poorly water-soluble drugs. PTB Reports; 2(3): 47-51.
2. Ridhurkar D, Pillai R, Dhawan S (2012) Leveraging the benefits offered by HME over traditional processing techniques to enhance the solubility of the drug September/October BioPharma Asia 16-25.
3. Patil H, Tiwari R, Repka M (2016) Hot-Melt Extrusion: from theory to application in pharmaceutical formulation. AAPS PharmSciTech 17(1): 20-42.
4. Wang W, Kang Q, Liu N, Zhang Q, Zhang Y, Li H (2014) Enhanced dissolution rate and oral bioavailability of Ginkgo biloba extract by preparing solid dispersion via hot-melt extrusion. Fitoterapia.102:189-97.
5. Repka M, Bandari A, Kallakunta S (2018) Melt extrusion with poorly soluble drugs - An integrated review. International Journal of Pharmaceutics, 535(1-2), 68-85.